Filing Flows › Indivior Pharmaceuticals (INDV) › Q3 2026 › vs Q2 2026
Indivior Pharmaceuticals (INDV) Q3 2026 vs Q2 2026 (quarter over quarter)
Indivior Pharmaceuticals's revenue rose $13.0M (+4%) from $343M in Q2 2026 to $356M in Q3 2026. Gross margin 85.7% against 85.7% (-0.0 pts).
Indivior Pharmaceuticals, Q3 2026: revenue $356M (+13% year over year), operating margin 50.6%, net earnings $137M, operating cash flow $97.0M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 85.7% | 85.7% | -0.0 pts |
| Operating margin | 50.6% | 46.6% | +3.9 pts |
| Net margin | 38.5% | 35.6% | +2.9 pts |
| Free cash flow margin | 23.3% | 64.7% | -41.4 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $356M | $343M | $13.0M | +4% |
| Gross profit | $305M | $294M | $11.0M | +4% |
| Cost of revenue | $51.0M | $49.0M | $2.0M | +4% |
| Other income, net | $2.0M | $0 | $2.0M | — |
| Operating profit | $180M | $160M | $20.0M | +12% |
| Operating expenses | $125M | $134M | −$9.0M | -7% |
| Pre-tax earnings | $182M | $160M | $22.0M | +14% |
| Research & development | $5.0M | $12.0M | −$7.0M | -58% |
| SG&A | $119M | $122M | −$3.0M | -2% |
| Net earnings | $137M | $122M | $15.0M | +12% |
| Income tax | $45.0M | $38.0M | $7.0M | +18% |
| Depreciation & amortization | $1.0M | $2.0M | −$1.0M | -50% |
| Share-based compensation | $8.0M | $11.0M | −$3.0M | -27% |
| Working capital & other | $49.0M | −$94.0M | $143M | — |
| Operating cash flow | $97.0M | $229M | −$132M | -58% |
| Free cash flow (OCF − capex) | $83.0M | $222M | −$139M | -63% |
| Capital expenditures | $14.0M | $7.0M | $7.0M | +100% |
Questions
How much did Indivior Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Indivior Pharmaceuticals's revenue rose $13.0M (+4%) from $343M in Q2 2026 to $356M in Q3 2026. Gross margin 85.7% against 85.7% (-0.0 pts).